- A
bispecific monoclonal antibody (BsMAb, BsAb) is an
artificial protein that can
simultaneously bind to two
different types of
antigen or two different...
-
United States in June 2023, and in the
European Union in July 2023.
Bispecifically binds CD20 and CD3 to
engage T-cells.
Mosunetuzumab was
approved for...
-
immune response is the
class of
drugs termed bispecific T-cell
engagers (BITE), or
sometimes simply bispecific antibodies. The
first drug in this
class approved...
- Deal". WSJ.
Retrieved April 10, 2024. "J&J Buys
Proteologix for $850M,
Bispecific Antibodies for
Atopic Dermatitis". BioSpace. May 16, 2024.
Retrieved August...
- antigens, in
which case they are
types of
bispecific antibodies. The
furthest developed of
these are
bispecific tandem di-scFvs,
known as bi-specific T-cell...
- for the
treatment of extensive-stage
small cell lung cancer. It is a
bispecific T-cell
engager that
binds delta-like
ligand 3 and CD3. The most common...
-
Along scFv and Fab fragments,
diabodies or
bispecific recombinant antibodies are the
third major format.
Bispecific antibodies combine two
different antigen...
- well as
relapsed or
refractory B-cell
precursor ALL.
Blinatumomab is a
bispecific T-cell
engager (BiTE). It
enables a patient's T
cells to
recognize malignant...
-
brand name Columvi, is a
bispecific monoclonal antibody used for the
treatment of
large B-cell lymphoma. It is a
bispecific CD20-directed CD3 T-cell engager...
- for the
treatment of
diffuse large B-cell lymphoma.
Epcoritamab is a
bispecific CD20-directed CD3 T-cell engager.
Epcoritamab was co-developed by AbbVie...
